Paris (France), Copenhagen (Denmark)– Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announces the publication of its 8^th Shareholders Letter.

This latest Shareholders Letter provides an update on Onxeo’s major achievements in 2015 with a focus on the positive results of the Phase I clinical trial of Bel-CHOP (association of belinostat with CHOP) and this quarters’ meetings between the Company and individual investors.

The Shareholders Letter is available on the company’s website at: www.onxeo.com (Media or Investors/Shareholders section).

151217EN_Shareholders-Letter

Onxeo-Shareholders-Letter-December-2015